Angiogenesis is accomplished by a series of sequential steps involving the motility and growth of endothelial cells: initiation and termination of these processes is tightly controlled by the balance between stimulatory and inhibitory factors. 1 Therefore, the delivery of inhibitory molecules and/or the removal of angiogenesis inducers could represent an effective approach to target and suppress tumor angiogenesis. Over the last decade, a number of anti-angiogenic agents were demonstrated to derive from a proteolytic cleavage of native proteins, as is the case for angiostatin, 2 endostatin, 3 platelet factor 4 (PF4), 4 or the 16-kDa N-terminal fragment of prolactin (16K PRL).
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Angiogenesis is accomplished by a series of sequential steps involving the motility and growth of endothelial cells: initiation and termination of these processes is tightly controlled by the balance between stimulatory and inhibitory factors. 1 Therefore, the delivery of inhibitory molecules and/or the removal of angiogenesis inducers could represent an effective approach to target and suppress tumor angiogenesis. Over the last decade, a number of anti-angiogenic agents were demonstrated to derive from a proteolytic cleavage of native proteins, as is the case for angiostatin, 2 endostatin, 3 platelet factor 4 (PF4), 4 or the 16-kDa N-terminal fragment of prolactin (16K PRL). 5 These factors, being 'natural' inhibitors of angiogenesis, are good candidates for an antiangiogenic therapy, as they should be much better tolerated by a patient than exogenous, synthetic drugs. Under most circumstances, however, angiogenesis inhibition appears to be cytostatic rather then cytotoxic, and therefore tumor growth inhibition would probably require prolonged maintenance therapy with the anti-angiogenic agents. The maintenance of this pro-
els. These results suggest that therapeutic strategies aiming to block tumor progression through the inhibition of tumorassociated angiogenesis, should not only provide large numbers of angiogenesis inhibitors, but also target the angiogenic factors produced by tumor cells. Moreover, the data described herein may confirm recent findings from other groups which indicate that in order to successfully counteract tumor progression, drugs inhibiting new blood vessel formation should be employed in combination with traditional anti-tumor strategies, such as chemotherapy or radiotherapy.
Gene Therapy (2002) 9, 297-302. DOI: 10.1038/sj/gt/3301652 longed systemic state may be expensive and problematic, but not necessary for treating localized malignancy, such as brain tumors. Therefore, in vivo gene transfer mediated by retroviral vectors offers the potential for creating an isolated anatomic region of angiogenesis inhibition by the local transduction of genes encoding antiangiogenic proteins. Abnormal angiogenesis is particularly evident in gliomas, 6, 7 which represent an excellent model for studying the effects of angiogenesis inhibition. Among 'natural' inhibitors of angiogenesis, we have chosen PF4, a 70-aminoacid protein normally found within the ␣granules of platelets, 8 and 16KrPRL. Both factors have been shown to be potent inhibitors of angiogenesis in vitro and in vivo. 5, [9] [10] [11] In this study, we report the construction of retroviral vectors encoding for a secreted form of human PF4 (sPF4), for 16KrPRL, and a selection gene. Here we show that this tricistronic vector actively transduces and expresses all the genes in a rat glioma cell line (C6), inhibiting the capability that these cells have to promote fundamental steps of angiogenesis, such as endothelial cell migration and the formation of an endothelial cell tube network. However, this tricistronic vector is not able to stop tumor growth in vivo.
First, we constructed bicistronic retroviral vectors carrying only one of the two antiangiogenic genes and the selection gene Puromycin N-acetyl transferase (pac) (Figure 1 ), and then, starting from these bicistronic plasmids, we assembled a tricistronic vector. This construct carried the cDNAs for pac and the anti-angiogenic factors 16KrPRL and sPF4 ( Figure 1 ). The therapeutic retroviruses were engineered by inserting 16KrPRL and sPF4 cDNAs into the MoMLV-based vector pBabepuro, 12 originally carrying the long terminal repeats (LTRs) and packaging site () regions from the mouse Moloney leukemia tumor virus, and the pac cDNA for in vitro selection. In the tricistronic vector, the transcription of 16krprl is controlled by the 5ЈLTR, while transcription of pac and spf4 is coordinately controlled by SV40 promoter/ enhancer; spf4 cDNA is here preceded by an IRES (ECMV internal ribosome binding site) that ensures the correct translation of the two protein products. 13, 14 Genes and gene-linkers were checked by standard gene sequencing.
Single CRIP (amphotropic retroviral packaging cells) clones were selected for the bicistronic and for the tricistronic constructs and analyzed for infectivity titer; one clone producing supernatant titers of 1 × 10 6 c.f.u. was chosen for each construct, and tested by RT-PCR for the expression of the corresponding mRNAs, and then used for stable infection of C6 cells. Retrovirally infected C6 rat glioblastoma cells were selected for puromycin resistance and the expression of 16krprl and spf4 was tested by RT-PCR, Western blot and ELISA analysis ( Figure 2 ). As expected, C6 cells transduced with retroviral vectors encoding for sPF4 and/or for 16KrPRL showed transcription of the corresponding mRNAs ( Figure 2a ). We detected 16KrPRL protein in cell lysates by Western blot, both in bicistronic and in tricistronic vector-infected cells (Figure 2b ), whereas we were able to detect sPF4 secretion into transduced cell-conditioned media, by using the more sensitive method of ELISA (Figure 2c ).
Consistent with the high level of angiogenesis found in gliomas in vivo, 15 conditioned medium from C6 cells was capable of promoting angiogenesis steps, such as endothelial cell migration and growth in vitro ( Figure 3) . Although C6 is a rat cell line, its conditioned medium promoted human endothelial cell growth and migration to the same extent as the conditioned medium of U87 cells (Figure 3a and b) , a human glioma cell line. This is in agreement with previous work indicating that the structure of angiogenic factors is conserved among different species. 16 Experiments were then performed to assess the biological activity of the vector-encoded sPF4 and 16KrPRL. No specific effect was shown on human umbilical vein endothelial cells (HUVEC) proliferation. In particular, conditioned media from C6 cells transduced with sPF4 or 16KrPRL affected HUVEC growth to the same extent as conditioned media from empty vector-infected cells (data not shown). This is different from previous work indicating that both 16KrPRL and sPF4 can inhibit endothelial cells growth. 5, 17 However, those results were obtained with protein values (40-100 nM) 5 much higher than those likely to be present in our experimental system, and possibly far from the amounts reasonably predictable in an in vivo system. In contrast, we observed a specific and significant inhibitory action of both factors at this dosage on the migration of endothelial cells, and importantly, on endothelial tube formation. Specifically, transduction with the sPF4-or 16KrPRL-expressing vectors inhibited, by 46% and 44% respectively, C6 capability of promoting HUVEC directional migration (Figure 3c ). Noticeably, culture medium from C6 cells expressing both factors inhibited endothelial cell migration to a greater extent (Ϫ67%) than individual factor-transduced cells (Figure 3c ). Moreover, while conditioned media obtained from wild-type C6 cells induced HUVE cells to form tube-like structures to the same extent as the angiogenic factor vascular endothelial growth factor (VEGF) (Figure 4a and c), C6 cells lost their angiogenic capabilities upon transduction with vectors expressing 16KrPRL and/or sPF4 (Figure 4d-f) . In contrast, transduction with empty vector did not affect C6 capability of promoting the formation of an endothelial cell tube network ( Figure  4b ). The specific and remarkable effects exerted by all types of supernatants on the inhibition of HUVEC migration are solid evidence in favor of the secretion of both factors in the extracellular compartment, even if we could detect 16KrPRL only in cell lysates, and not in supernatants, while we demonstrated sPF4 secretion, probably thanks to the more sensitive detection method (ELISA versus Western blot, and antibody versus antiserum). Our data are also in agreement with the fact that inhibitors of angiogenesis are known to act at extremely low concentrations. 16, 18 It is of interest that the synthesis and release of these anti-angiogenic factors do not affect C6 proliferation rate, nor C6 ability of invading the extracellular matrix (data not shown). These results confirm that the inhibitory effects of sPF4 and 16KrPRL are specific for endothelial cells.
Animal studies were then carried out to evaluate whether the sPF4-16KrPRL vector had any capability of inhibiting or blocking the development and/or pro- Figure 1) , plus a reverse primer specific for the cyclophilin mRNA, used as a housekeeping internal control. 23 The PCR reaction was carried out using primers specific for 16KrPRL and for sPF4 (see Figure 1) , and a couple of primers for cyclophilin ( 
forward 5ЈAGAAGGACATGAGCATTGTGGAAG3Ј, reverse 5ЈTGCTCTCCTGAGCTACAGAAGGAA3Ј). The 456 bp 16KrPRL, 315 bp sPF4 and the 158 bp cyclophilin amplified products were analyzed by 2% agarose gel electrophoresis. (b) Western blot analysis of 16KrPRL production in retrovirally transduced C6 cells. Protein extracts were resolved by SDS-PAGE (4-14%), subsequently transferred to PVDF transfer membrane, and incubation was performed with 1/2000 diluted rabbit polyclonal anti-ratPRL antiserum (NIDDK). The secondary antibody was a 1:1000 dilution of a horseradish peroxidase-linked anti rabbit IgG (Amersham-Pharmacia, Cologno Monzese, Italy), detected by ECL Western blotting analysis system (Amersham-Pharmacia). A 16 kDa specific band is detected in bicistronic (lane 2) and tricistronic (lane 4) construct-infected cells. No 16KrPRL protein was detected in non-transduced (lane 1) or empty vector transduced (lane 3) C6 lysates. (c) ELISA detection of sPF4 secretion in retrovirally transduced C6 cells. Twenty-four hours after plating, cells (1 × 10 6 ) were passed to 'serum-free' DMEM for 48 h, and then supernatants were collected, cleared by a brief centrifugation, and concentrated with centrifugal filters Centricon Plus-20, Biomax-5 (Millipore, Bedford, MA, USA). A standard non-sandwich ELISA was set up using a 100 ng/well final concentration of rabbit anti-human PF4 polyclonal primary antibody (PeProtec-EC-LTD) and a 1:1000 dilution of horseradish peroxidase-linked anti-rabbit IgG secondary antibody (Amersham-Pharmacia). The PF4 concentrations (ng/ml) in supernatants from non-infected, empty vector-infected (pBabepuro), and bicistronic (PF4) or tricistronic (PF4+16KrPRL) construct-infected C6 cells are shown. Numerical values are: 0.1 ng/ml for C6, 0.11 ng/ml for pBabepuro, 2.0 ng/ml for pBabepuro-sPF4, 0.32 ng/ml for pBabepuro16KrPRL-sPF4.
gression of glioblastomas. Malignant tumors induced in the right cerebral hemisphere of Wistar rats are very aggressive and usually lethal to the animal within 15 to 25 days. 19 We inoculated 10 rats on day 0 with a 1:1 mixture of rat glioblastoma C6 cells and CRIP-tricistronic vector-producing cells (5 × 10 5 cells of each). As a control, nine more rats were inoculated with a 1:1 mixture of C6 and CRIP packaging an empty vector (pBabe-puro). As shown in Figure 5a , although there was a slight increase in survival time in animals treated with the antiangiogenic retrovirus, the difference is not statistically significant and all animals died by 23 days from inoculum. Tumor growth was followed by magnetic resonance, which further confirmed the inefficacy of this anti-angiogenic retrovirus in stopping tumor growth or even in reducing it (Figure 5b) . No toxicity effect was observed in control animals injected with CRIP cells alone and none of them developed tumors.
In order to exclude any immunological effect towards CRIP cells, which might counteract 16KrPRL and sPF4 antiangiogenic action, we performed in vivo experiments in which we inoculated C6 cells permanently expressing 16KrPRL and sPF4 into rat brain. In neither condition did we observe significant retardation of tumor growth or reduction in tumor vascularization (data not shown). We therefore believe that the amount of anti-angiogenic factors produced in situ in the animal model is too low to counteract tumor growth.
In conclusion, here we have shown that the antiangiogenic activity of a tricistronic vector was sufficient to strongly impair endothelial cell locomotion, the initial step of angiogenesis in vitro. As a consequence, inhibition of endothelial cell migration is sufficient to heavily impair in vitro angiogenesis analyzed as endothelial tube Gene Therapy formation. In spite of these results, however, in vivo experiments showed that retroviruses released by the producer cells cannot block the development or progression of glioblastoma, following C6 cell injection in rats. Thus, the use of the two natural anti-angiogenic factors 16KrPRL and sPF4 cloned in a retroviral vector is not an adequate therapeutic tool for the gene therapy of glioblastoma. In this regard, multicistronic vectors may be needed to encode for even more factors, and delivery and expression systems must be improved. Moreover, a combination of strategies such as anti-angiogenic plus immunomodulatory factors, chemotherapy or radiotherapy should be tried. Indeed, recent results show that the combination of TNP-470, a proven anti-angiogenic compound, with ionizing radiation, 20 or of A6, an antiangiogenic fragment of urokinase plasminogen activator, with cisplatin, 21 are very efficient in inhibiting neovascularization and growth of experimentally induced tumors in mice. More strikingly, the most powerful among these combination therapies involves the anti-angiogenic agent A6, which inhibits only endothelial cell migration. Specifically, as for 16KrPRL and sPF4, co-treatment with A6 and cisplatin shows an antitumor activity much stronger than that shown by the single treatment with each agent alone. 21 The same is true for the association of a low and semicontinuous chemotherapy regimen with PEX, an anti-angiogenic fragment of matrix metalloproteinase-2, which results in a marked decrease in tumor volume and vascularity, and prolonged survival, as compared with chemotherapy or anti-angiogenic therapy alone. 22 Furthermore, inhibition of specific tumor angiogenesis may also be achieved by using direct antagonists targeting angiogenic factors produced by tumor cells (basic fibroblast growth factor, bFGF, VEGF, etc). For example, antisense oligonucleotides and ribozymes, exerting an 'upstream' inhibition of angiogenic factors expression, or antibodies and receptor competitors, blocking directly angiogenic factors and their receptors, might be ideally coupled to and act synergistically with natural inhibitors of angiogenesis (eg PF4 and 16KrPRL), thus targeting at the same time both tumor and endothelial cells.
